Unicycive Therapeutics’ (UNCY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $5.50.

Unicycive Therapeutics Stock Down 1.6 %

Shares of UNCY opened at $0.53 on Wednesday. The firm’s 50 day moving average price is $0.69 and its 200 day moving average price is $0.51. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UNCY. Virtu Financial LLC boosted its holdings in Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after acquiring an additional 62,881 shares during the period. XTX Topco Ltd bought a new stake in Unicycive Therapeutics during the 3rd quarter valued at approximately $29,000. Walleye Capital LLC acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at approximately $2,040,000. Acuta Capital Partners LLC acquired a new position in shares of Unicycive Therapeutics during the third quarter worth approximately $807,000. Finally, Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics in the third quarter valued at approximately $3,491,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.